Moberg Pharma AB (publ)

OM:MOB Stock Report

Market Cap: SEK 455.3m

Moberg Pharma Management

Management criteria checks 1/4

Moberg Pharma's CEO is Anna Ljung, appointed in May 2019, has a tenure of 5.67 years. total yearly compensation is SEK3.51M, comprised of 56.6% salary and 43.4% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth SEK71.93K. The average tenure of the management team and the board of directors is 5.3 years and 2.2 years respectively.

Key information

Anna Ljung

Chief executive officer

SEK 3.5m

Total compensation

CEO salary percentage56.6%
CEO tenure5.7yrs
CEO ownership0.02%
Management average tenure5.3yrs
Board average tenure2.2yrs

Recent management updates

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14
We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08
Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Nov 16
Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Jan 17
Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

Dec 03
Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

CEO Compensation Analysis

How has Anna Ljung's remuneration changed compared to Moberg Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 18m

Jun 30 2024n/an/a

-SEK 23m

Mar 31 2024n/an/a

-SEK 23m

Dec 31 2023SEK 4mSEK 2m

-SEK 21m

Sep 30 2023n/an/a

-SEK 18m

Jun 30 2023n/an/a

-SEK 16m

Mar 31 2023n/an/a

-SEK 16m

Dec 31 2022SEK 3mSEK 2m

-SEK 16m

Sep 30 2022n/an/a

-SEK 17m

Jun 30 2022n/an/a

-SEK 16m

Mar 31 2022n/an/a

-SEK 16m

Dec 31 2021SEK 2mSEK 1m

-SEK 16m

Sep 30 2021n/an/a

SEK 8m

Jun 30 2021n/an/a

SEK 7m

Mar 31 2021n/an/a

SEK 5m

Dec 31 2020SEK 3mSEK 2m

SEK 7m

Jun 30 2020n/an/a

SEK 20m

Jun 30 2019SEK 476kSEK 151k

-SEK 8m

Compensation vs Market: Anna's total compensation ($USD314.77K) is above average for companies of similar size in the Swedish market ($USD228.21K).

Compensation vs Earnings: Anna's compensation has increased whilst the company is unprofitable.

CEO

Anna Ljung (44 yo)

5.7yrs

Tenure

SEK 3,511,000

Compensation

Ms. Anna Ljung, M.Sc. Econ., BA serves as Chairperson of Biosergen AB since June 14, 2024. She served as Chairman of The Board at OncoZenge AB (publ) until August 2023. She joined company since 2020.Ms. L...

Leadership Team

NamePositionTenureCompensationOwnership
Anna Ljung
Chief Executive Officer5.7yrsSEK 3.51m0.016%
SEK 71.9k
Marie Moberg
Co-Founder18.8yrsSEK 193.70kno data
Mark Beveridge
Vice President of Finance5.3yrsno data0.033%
SEK 151.5k
Christina Erixon
Head of Pharmaceutical Development & Operations1.2yrsno datano data
Amir Tavakkol
Chief Scientific Officerno datano datano data
Gunilla Wengström
Senior Director of Sales & Marketing6yrsno datano data
Anders Broijersen
Chief Medical Officer2.2yrsno data0.000020%
SEK 91.1
Robert Ehrl
Head of Supply1.2yrsno datano data

5.3yrs

Average Tenure

55.5yo

Average Age

Experienced Management: MOB's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Howard Maibach
Member of Scientific Advisory Boardno datano datano data
Jonas Ekblom
Directorless than a yearno datano data
Hakan Wallin
Independent Director1.7yrsSEK 99.00kno data
Nikolaj Sorensen
Independent Director3.7yrsSEK 170.00k0.17%
SEK 782.1k
Jan Faergemann
Member of Scientific Advisory Boardno datano datano data
Lennart Emtestam
Member of Scientific Advisory Boardno datano datano data
Johan Heilborn
Member of Scientific Advisory Boardno datano datano data
Bernt Lindelöf
Member of Scientific Advisory Boardno datano datano data
Kerstin Strinnholm
Independent Chairman of the Board2.7yrsSEK 360.00k0.19%
SEK 877.1k

2.2yrs

Average Tenure

60.5yo

Average Age

Experienced Board: MOB's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 03:20
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Moberg Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bjorn RydellABG Sundal Collier Sponsored
Klas PykNordea Markets
Mats HyttingeRedeye